From: Influence of human chorionic gonadotrophin during ovarian stimulation: an overview
 | Patients (N) | Treatment | Testing for | Primary outcomes |
---|---|---|---|---|
Menopur® studies | ||||
EISG (EISG, Fertil Steril 2002 [10]) | N = 781 | Menopur® versus Gonal-F® 225 IU fixed dose for 5 days of either HP-hMG or rFSH alfa | Non-inferiority | Efficacy: OPR: 25% HP-hMG versus 22% rFSH alfa, P = 0.17 Safety: Adverse events probably and possibly related to the medication; 14.2% HP-hMG vs 13.0% rFSH alfa OHSS: 1.9% HP-hMG vs 1.2% rFSH alfa Miscarriage: 25.4% HP-hMG vs 27.6% rFSH alfa |
MERiT (Andersen AN, et al. Hum Reprod 2006 [11]) | N = 731 | Menopur® versus Gonal-F® 225 IU fixed dose for 5 days of either HP-hMG or rFSH alfa, followed by individual adjustments according to the patient’s follicular response | Non-inferiority | Efficacy: OPR per started cycle: 27% HP-hMG vs 22% rFSH alfa (95% CI: 0.89 to 1.75, P = 0.204) Safety: Incidence of adverse events: 51% HP-hMG vs 49% rFSH alfa OHSS: 4% HP-hMG vs 3% rFSH alfa Early pregnancy loss: 26% HP-hMG vs 32% rFSH alfa |
Bosch E, et al. (Hum Reprod 2008 [78]) | N = 280 | Menopur® versus Gonal-F® 225 IU fixed starting dose for 2 days of either HP-hMG or rFSH alfa, followed by individual adjustments according to serum oestradiol levels | Non- inferiority | Efficacy: OPR per randomised patient: 35.0% HP-hMG (95% CI: 27.1 to 43.5) vs 32.1% rFSH alfa (95% CI: 24.5 to 40.6) Safety: Cycles cancelled due to risk of OHSS: 6.4% HP-hMG vs 3.6% rFSH alfa, P = 0.27 Clinical OHSS: 1.64% HP-hMG vs 1.59% rFSH alfa Pregnancy loss: 0.82% HP-hMG vs 0.79% rFSH alfa |
MEGASET (Devroey P, et al. Fertil Steril 2012 [12]) | N = 749 | Menopur® versus Puregon® 150 IU fixed dose for 5 days of either HP-hMG or rFSH beta, followed by dose adjustments if required of 75 IU increments, not more than every 4 days | Non-inferiority | Efficacy: OPR in the PP population: 30% HP-hMG versus 27% rFSH beta, 95% CI: 3.0% (− 3.8 to 9.8) Safety: Incidence of adverse events: 39% HP-hMG vs 37% rFSH beta OHSS: 3% in each treatment group Interventions associated with excessive response or to prevent early OHSS were higher in rFSH beta group (P = 0.025) |
MEGASET-HR (Witz C, et al. Fertil Steril 2020 [79]) | N = 620 Patients with serum AMH ≥5 ng/mL | Menopur® versus Gonal-F® 150 IU fixed start dose of either HP-hMG or rFSH alfa | Non-inferiority | Efficacy: OPR: 35.5% HP-hMG vs 30.7% rFSH alfa, 95% CI: 4.7% (−2.7 to 12.1) Safety: OHSS: 9.7% HP-hMG versus 21.4% rFSH alfa, 95% CI: − 11.7% (− 17.3 to − 6.1), P < 0.05 Incidence of treatment emergent adverse events: 57.7% HP-hMG vs 70.6% rFSH alfa Cumulative early pregnancy loss (fresh/frozen ET): 14.5% HP-hMG vs 25.5% rFSH alfa |
Taronger R, et al. (Eur J Obstet Gynecol Reprod Biol 2018 [80]) | N = 234 Poor ovarian responders | Menopur® versus Elonva® 150 μg single dose of CFA followed by 300 IU HP-hMG after Day 8 until criteria for triggering ovulation were met, versus 300 IU continuous daily dose of HP-hMG | Non-inferiority | Efficacy: OPR per started cycle: 20.2% HP-hMG vs 15.2 CFA, 95% CI: −5 (− 15.1 to 5.0), P = 0.33 Safety: Cancellation rate: 5.5% HP-hMG vs 3.6% CFA, P = 0.49 |
Errázuriz J, et al. (Front Endocrinol 2019 [81]) | N = 917 Poor ovarian responders | Menopur® versus Elonva® 150 μg single dose of CFA followed by ≥300 IU HP-hMG after Day 8 until criteria for triggering ovulation were met, versus 7 x fixed daily doses of 300–450 IU HP-hMG | Non-inferiority | Efficacy: Cumulative LBR: 16.9% HP-hMG vs 11.8% CFA + HP-hMG; P = 0.03 |
Pergoveris® studies | ||||
PERSIST (Behre, et al. RBM Online 2015 [82]) | N = 202 Women aged 36–40 years | Pergoveris® versus Gonal-F® 300 IU fixed starting dose of rhFSH/rhLH from stimulation on Day 1 or rhFSH on stimulation on Days 1–5 followed by rhFSH + rhLH from stimulation Day 6. Dose adjustments were permitted from Day 6 | Non-inferiority | Efficacy: Number of oocytes retrieved: 9.7 rhFSH/rhLH vs 10.9 rFSH alfa, 95% CI: –3.15 to 0.59 Safety: Adverse events reported: 31.1% rhFSH/rhLH vs 32.3% rFSH alfa Serious AEs: 2% rhFSH/rhLH vs 0% rFSH alfa OHSS: 3.9% rhFSH/rhLH vs 5.1% rFSH alfa |
ESPART (Humaidan, et al. Hum Reprod 2017 [83]) | N = 939 Poor ovarian responders | Pergoveris® versus Gonal-F® Fixed starting dose of 300 IU rhFSH + 150 IU rhLH (Pergoveris®) or 300 IU rFSH alfa (Gonal-F®). Dose adjustments were permitted from Day 4, at increments of 75 IU of rhFSH with a maximum daily dose of 450 IU (concomitant automatic adjustments of rhLH were made with a maximum daily dose of 325 IU) | Superiority | Efficacy: Number of oocytes retrieved: 3.3 rhFSH/rhLH vs 3.6 rFSH alfa, 95% CI: –0.24 (−0.74 to 0.27); P = 0.182 Safety: TEAEs: 19.9% rhFSH/rhLH vs 26.8% rFSH alfa Serious TEAEs: 1.7% rhFSH/rhLH vs 3.6% rFSH alfa, 95% CI: 0.46 (0.19 to 1.09) One incidence of OHSS in the rhFSH/rhLH group |